Receptor affinity and phosphodiesterases 4B and 10A activity of octahydro- and 6,7-dimethoxy-3,4-dihydro-isoquinolin-2-(1H)-yl-alkyl derivatives of imidazo- and pyrimidino[2,1-f]purines by Zagórska, Agnieszka et al.
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 73 No. 2 pp. 369ñ377, 2016 ISSN 0001-6837
Polish Pharmaceutical Society
There has been a shift in the theoretical frame-
work addressing the pathophysiology of psychiatric
disorders during the last decade. There is growing
evidence that, in addition to neurotransmitters and
their receptors, various signal transduction pathways
may be linked to the pathophysiology of major psy-
chiatric disorders. A complex mechanism of action
characterizes drugs used in the pharmacotherapy of
anxiety, depression, and schizophrenia; most of
them are compounds with affinity for serotoniner-
gic- (5-HT1A,2A,6,7) and dopaminergic (D2,3)-type
receptors (1ñ4). The transduction of signals from 5-
HT/D receptors (5-HTRs, DARs) is associated with
the activation of second messenger pathways, which
are mainly responsible for the increased level of the
cyclic adenosine monophosphate (cAMP).
The involvement of the upstream and down-
stream components of this system provides a new
framework in the treatment of psychiatric disorders
(5). Therefore, cyclic nucleotide phosphodiesterases
(PDEs), enzymes which degrade cAMP by hydroly-
sis of phosphodiester bonds, have been an attractive
therapeutic target. In animal models, inhibitors of
PDE4 and PDE10A by receptor-independent mech-
anisms reproduced antidepressant-like and antipsy-
chotic effect (6, 7).
In our previous papers, we have described
mixed serotonin/dopamine receptor binding profile
of long-chain arylpiperazine (LCAP) derivatives
with imidazo- and pyrimidino[2,1-f]purine moiety
as cyclic amide core in terminal fragment (8ñ10).
On the contrary, the early synthetic inhibitors of
PDE belong to alkylxanthine or they are closely
related to the xanthine ring derivatives. Nowadays,
inhibitors of PDE4 and PDE10A are based on
RS25344 or papaverine, respectively (Fig. 1) (11).
In this study, our aim was to investigate struc-
ture-affinity relationships for the 5-HT1A,6,7 and
dopaminergic D2 receptors and inhibition of PDE4B
and PDE10A in a group of imidazo- and pyrimidi-
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no[2,1-f]purines. Structural modifications com-
prised introduction of octahydro- and 3,4-dihydro-
isoquinolin-2(1H)-yl-alkyl moieties (instead of
LCAP), as structures derived from papaverine, SB-
277011 (12), and PZ-376 (13) (Fig. 1), respectively.
Further studies focused on the effect of alkylene
chain length and the presence of imidazo- and/or
exocyclic amide moiety annelated on purine hetero-
cyclic system on the receptor affinity and PDEsí
inhibition.
EXPERIMENTAL
Chemistry
Schemes 1 and 2 present the structures of the
investigated compounds and their syntheses. As can
be seen in Scheme 1, a series of derivatives of 1,3-
dimethyl-8-(octahydroisoquinolin-2(1H)-yl)alkyl-
1H-imidazo[2,1-f]purine-2,4(3H,8H)-diones and 8-
(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl)alkyl)-1,3-dimethyl-1H-imidazo[2,1-f]purine-
2,4(3H,8H)-diones (1ñ7) were prepared in multistep
synthesis. In the first step, the alkylation of decahy-
droisoquinoline and 6,7-dimethoxy-1,2,3,4-tetrahy-
droisoquinoline (I, II) with 2-(bromoalkyl)-1H-
isoindoline-1,3(2H)-diones IIIñIV afforded corre-
sponding derivatives VñVIII. Next, hydrolysis of
the 1H-isoindoline-1,3(2H)-dione group with 65%
hydrazine monohydrate aqueous solution afforded
intermediates IXñXII, which reacted with 7-ketonyl
derivatives of 8-bromo-1,3-dimethyl-3,7-dihydro-
1H-purine-2,6-dione (XIIIñXIV) (8) to provide the
final derivatives (1ñ7). According to the previously
described method, the 9-octahydroisoquinolin-
2(1H)-yl and 6,7-dimethoxy-3,4-dihydroisoqiuno-
lin-2(1H)-yl-alkyl derivatives of 1,3-dimethyl-
pyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones
(8ñ12) were synthesized by alkylation of the corre-
sponding isoquinolin-2-yl derivatives (I, II) with 
7-bromo-9-(chloroalkyl)-1,3-dimethylpyrimido[2,1-
f]purine-2,4,8(1H,3H,9H)-triones (XVñXVII) (9).
The structures of newly synthesized compounds
1ñ12 were confirmed by 1H NMR and 13C-NMR
spectra, LC/MS and elemental analyses. The inves-
tigated compounds were pharmacologically tested
as free bases. 1H and 13C NMR spectra were record-
ed on Varian Mercury VX-300 MHz spectrometer,
in CDCl3 solutions, using TMS (δ = 0.00 ppm) as an
internal standard. The J values are in Hertz (Hz),
and splitting patterns are designated as follows: s
(singlet), d (doublet), t (triplet), m (multiplet).
Liquid chromatographyñmass spectrometry
(LC/MS) analyses were performed on Waters
Acquity TQD apparatus with eλ DAD detector.
Figure 1. Representatives of the multi-receptor ligands and PDE inhibitors
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Compound n R Amine 
1 4 -H octahydroisoquinolin-2(1H)-yl  
2 5 -H octahydroisoquinolin-2(1H)-yl  
3 4 -CH3 octahydroisoquinolin-2(1H)-yl  
4 5 -CH3 octahydroisoquinolin-2(1H)-yl  
5 4 -H 6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl 
6 5 -H 6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl  
7 4 -CH3 6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl  
Scheme 1. Synthesis of 1,3-dimethyl-8-(octahydroisoquinolin-2(1H)-yl)alkyl-1H-imidazo[2,1-f]purine-2,4(3H,8H)-diones and 8-(6,7-
dimetoxy-3,4-dihydroisoquinolin-2(1H)-yl)alkyl)-1,3-dimethyl-1H-imidazo[2,1-f]purine-2,4(3H,8H)-diones (1-7). Reagents and condition
(a) K2CO3, butanol, reflux; (b) hydrazine, EtOH, reflux; (c) 2-methoxyethanol, reflux
Compound n Amine 
8 5 -H octahydroisoquinolin-2(1H)-yl  
9 4 -Br octahydroisoquinolin-2(1H)-yl  
10 4 -H 6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl  
11 5 -H 6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl  
12 4 -Br 6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl  
Scheme 2. Synthesis of 9-octahydroisoquinolin-2(1H)-yl and 6,7-dimethoxy-3,4-dihydroisoqiunolin-2(1H)-yl-alkyl derivatives of 1,3-
dimethyl-pyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones (8-12). Reagents and condition (a) acetonitrile, microwave, open vessel, 200 W,
1 h
amine (I or II)
amine (I or II)
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Electrospray ionization in positive mode (ESI+) was
used to acquire spectra. UV spectra were recorded in
200ñ700 nm range. UV chromatograms were used
for establishing the purity of compounds. All inves-
tigated final compounds had purity over 95%.
Elemental analyses were performed using Elemetar
Vario EL III apparatus and were found within ±
0.4% of the theoretical values. Melting points (m.p.)
were determined with a B¸chi apparatus and are
uncorrected. Thin-layer chromatography (TLC) was
performed on Merck silica gel 60 F254 aluminum
sheets, and spots were detected by their absorption
under UV light (λ = 254 nm). Column chromatogra-
phy separations were carried out on Merck Kieselgel
60 column. Microwave-assisted synthesis was per-
formed in laboratory microwave Discover LabMate
reactor (CEM Corporation). All chemicals and
reagents for the synthesis were obtained from Alfa
Aesar (Karlsruhe,Germany), Sigma-Aldrich Co. (St.
Louis, United States) and Chempur (Piekary
ålπskie, Poland).
General procedure for the synthesis of 1,3-
dimethyl-8-(octahydroisoquinolin-2(1H)-
yl)alkyl-1H-imidazo[2,1-f]purine-2,4-(3H,8H)-
diones and 8-(6,7-dimethoxy-3,4-dihydroiso-
quinolin-2(1H)-yl)alkyl)-1,3-dimethyl-1H-imida-
zo[2,1-f]purine-2,4-(3H,8H)-diones 
A mixture of 7-ketonyl derivatives of 8-bromo-
1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione
XIII, XIV (5 mmol) with double amount of appro-
priate isoquinolin-2-yl-alkyl-amine (10 mmol)
(IXñXII) was refluxed in 2-methoxyethanol (20
mL) for 12 h. The solvent was removed in vacuo,
the obtained residue was purified by flash column
chromatography on silica gel using mixture of
CH2Cl2/MeOH = 9/1 or 9/0.7, v/v as an eluting sys-
tem. 
1,3-Dimethyl-8-(4-(octahydroisoquinolin-2(1H)-
yl)butyl)1H-imidazo[2,1-f]purine-2,4-(3H,8H)-
dione (1)
Obtained from IX and XIII in 60% yield as
cream solid; m.p. 96-98OC; 1H NMR (300 MHz,
CDCl3, δ, ppm): 7.40-7.39 (d, 1H, J = 2.3 Hz), 6.82-
6.81 (d, 1H, J = 2.3 Hz), 4.17 (t, 2H, J = 7.4 Hz),
3.59 (s, 3H), 3.43-3.41 (m, 4H), 2.64-2.52 (m, 2H),
2.16-1.85 (m, 3H), 1.76-1.62 (m, 8H); 13C NMR
(CDCl3, δ, ppm): 153.9, 151.9, 150.2, 147.5, 120.6,
114.9, 100.1, 58.6, 56.9, 55.3, 48.4, 39.5, 36.4, 31.3,
30.3, 30.1, 29.7, 29.3, 28.9, 26.7, 25.6, 24.9;
Analysis: calcd. for C22H32N6O4: C, 64.05; H, 7.82;
N, 20.37%; found: C, 65.12; H, 7.58; N, 20.07%.
LC/MS m/z calcd.: 412.52, found: 413.39.
1,3-Dimethyl-8-(5-(octahydroisoquinolin-2(1H)-
yl)pentyl)1H-imidazo[2,1-f]purine-2,4-(3H,8H)-
dione (2)
Obtained from X and XIII in 56% yield as
cream solid; m.p. 101-102OC; 1H NMR (300 MHz,
CDCl3, δ, ppm): 7.40-7.39 (d, 1H, J = 2.3 Hz), 6.83-
6.82 (d, 1H, J = 2.3 Hz), 4.15 (t, 2H, J = 7.4 Hz),
3.61-3.59 (m, 4H), 3.45-3.39 (m, 6H), 2.64-2.52 (m,
2H), 2.02-0.85 (m, 22H), 13C NMR (CDCl3, δ, ppm):
154.8, 151.3, 150.1, 145.0, 120.6, 114.9, 100.1,
58.6, 57.2, 55.3, 48.4, 39.5, 36.4, 32.1, 30.7, 29.6,
29.0, 28.8, 28.0, 26.1, 25.8, 25.1, 24.5; Analysis:
calcd. for C23H34N6O2: C, 64.76; H, 8.03; N, 19.70%;
found: C, 64.67; H, 7.98; N, 19.77%. LC/MS m/z
calcd.: 426.55, found: 427.41.
1,3,7-Trimethyl-8-(4-(octahydroisoquinolin-
2(1H)-yl)butyl)1H-imidazo[2,1-f]purine-2,4-(3H,
8H)-dione (3)
Obtained from IX and XIV in 88% yield as
cream solid; m.p. 128-129OC; 1H NMR (300 MHz,
CDCl3, δ, ppm): 7.18 (m, 1H), 4.07 (t, 2H, J = 7.4
Hz), 3.63 (s, 3H), 3.41 (s, 3H), 2.64-2.52 (m, 2H),
2.16-1.92 (m, 5H), 1.85-0.92 (m, 20H); 13C NMR
(CDCl3, δ, ppm): 153.9, 151.9, 150.2, 147.5, 132.4,
130.8, 128.7, 58.4, 58.1, 53.7, 48.4, 40.1, 38.7, 38.1,
30.4, 30.2, 28.9, 28.8, 26.7, 26.1, 25.8, 24.9, 14.0;
Analysis: calcd. for C23H34N6O2: C, 64.76; H, 8.03;
N, 19.70%; found: C, 64.72; H, 8.08; N, 19.66%.
LC/MS m/z calcd.: 426.55, found: 427.35.
1,3,7-Trimethyl-8-(5-(octahydroisoquinolin-
2(1H)-yl)pentyl)1H-imidazo[2,1-f]purine-2,4-
(3H,8H)-dione (4)
Obtained from X and XIV in 78% yield as
cream oil; 1H NMR (300 MHz, CDCl3, δ, ppm): 7.19
(m, 1H), 4.15 (t, 2H, J = 7.4 Hz), 3.63 (s, 3H), 3.41
(s, 3H), 2.64-2.52 (m, 2H), 2.02-0.85 (m, 25H); 13C
NMR (CDCl3, δ, ppm): 154.3, 151.3, 150.1, 149.3,
128.3, 110.3, 100.1, 58.6, 57.2, 53.1, 48.4, 39.5,
36.4, 32.1, 30.7, 30.2, 29.0, 28.8, 26.7, 26.1, 25.8,
25.1, 24.9, 13.9; Analysis: calcd. for C24H36N6O2: C,
65.43; H, 8.24; N, 19.07%; found: C, 65.48; H, 8.44;
N, 19.17%. LC/MS m/z calcd.: 440.58, found:
441.37.
8-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-
2(1H)butyl)1,3-dimethyl-1H-imidazo[2,1-
f]purine-2,4-(3H,8H)-dione (5)
Obtained from XI and XIII in 83% yield as
cream solid; m.p. 167-169OC; 1H NMR (300 MHz,
CDCl3, δ, ppm): 7.0-7.99 (d, 1H, J = 2.3 Hz), 6.92 (s,
1H), 6.64 (s, 2H), 6.55 (s,2H), 4.18 (t, 2H, J = 7.4 Hz),
3.86-3.81 (m, 6H), 3.59 (s, 3H), 3.43 (m, 3H), 3.20-
Receptor affinity and phosphodiesterases 4B and 10A activity of octahydro- and... 373
2.84 (m, 6H), 2.15-1.85 (m, 6H); 13C NMR (CDCl3, δ,
ppm): 154.8, 151.3, 149.1, 148.2, 146.7, 145.0, 126.8,
125.5, 120.6, 114.9, 111.4, 108.3, 100.1, 59.7, 56.5,
56.3, 56.2, 56.1, 55.6, 30.7, 29.6, 29.0, 27.9, 25.0;
Analysis: calcd. for C24H30N6O4: C, 61.79; H, 6.48; N,
18.01%; found: C, 61.87; H, 6.59; N, 18.07%. LC/MS
m/z calcd.: 466.53, found: 467.37.
8-(5-(6,7-Dimethoxy-3,4-dihydroisoquinolin-
2(1H)pentyl)1,3-dimethyl-1H-imidazo[2,1-
f]purine-2,4(3H,8H)-dione (6)
Obtained from XII and XIII in 64% yield as
cream solid; m.p. 217-219OC; 1H NMR: (300 MHz,
CDCl3, δ, ppm): 7.09 (d, 1H, J = 2.3 Hz), 6.92 (m,
1H), 6.64 (s, 1H), 6.55 (s, 1H), 4.18 (m, 2H), 3.86-
3.81 (m, 6H), 3.60 (s, 3H), 3.41 (m, 3H), 3.28-3.20
(m, 2H), 3.09-3.16 (m, 2H), 2.96-2.89 (m, 2H),
2.15-1.85 (m, 4H), 1.56-1.42 (m, 2H), 1.30-1.22 (m,
2H); 13C NMR (CDCl3, δ, ppm): 154.0, 152.1, 151.9,
148.8, 146.7, 145.2, 126.8, 125.0, 119.6, 114.8,
111.1, 109.2, 100.0, 60.1, 56.5, 56.3, 56.1, 56.0,
55.6, 30.2, 30.0, 39.9, 28.1, 27.3, 25.1; Analysis:
calcd. for C25H32N6O4: C, 62.48; H, 6.71; N, 17.49%;
found: C, 62.87; H, 6.59; N, 78.47%. LC/MS m/z
calcd.: 480.55, found: 481.39.
8-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-
2(1H)butyl)1,3,7-trimethyl-1H-imidazo[2,1-
f]purine-2,4(3H,8H)-dione (7)
Obtained from XI and XIV in 70% yield as
cream solid; m.p. 145-147OC; 1H NMR (300 MHz,
CDCl3, δ, ppm): 7.08-7.07 (m, 1H), 6.64 (s, 2H),
6.55 (s, 2H), 4.08 (m, 4H), 3.86-3.81 (m, 6H), 3.60
(s, 3H), 3.41 (m, 3H), 2.88-2.83 (m, 2H), 2.80-2.76
(m, 2H), 2.60-2.57 (m, 2H), 2.38 (s, 3H), 2.06-1.86
(m, 4H); 13C NMR (CDCl3, δ, ppm): 154.1, 151.9,
150.3, 147.66, 146.7, 145.0, 128.3, 127.1, 126.5,
111.4, 110.9, 109.3, 99.8, 60.1, 56.5, 56,4, 56.3,
56.2, 53.1, 30.7, 29.9, 29.0, 28.0, 27.3, 25.1, 13.1;
Analysis: calcd. for C25H32N6O4: C, 62.48; H, 6.71;
N, 17.49%; found: C, 62.77; H, 6.66; N, 17.47%.
LC/MS m/z calcd.: 480.55, found: 481.33.
General procedure for preparation of 9-octahy-
droisoquinolin-2(1H)-yl and 6,7-dimethoxy-3,4-
dihydroisoqiunolin-2(1H)-yl-alkyl derivatives of
1 , 3 - d i m e t h y l - p y r i m i d o [ 2 , 1 - f ] p u r i n e -
2,4,8(1H,3H,9H)-triones
The starting 9-bromoalkyl-1,3-dimethyl-
pirymido[2,1-f]purine-2,4,8-(1H,3H,9H)-triones
(XVñXVIII) were obtained according to the previ-
ously described procedure (9). A mixtures of
XVñXVII (0.5 mmol) with a twofold excess of
appropriate isoquinolin-2-yl derivatives in acetoni-
trile (4 mL) were exposed to microwave irradiation
for 1 h and power of MW oven (200 W). After evap-
oration of the solvent products 8ñ12 were purified
by flash column chromatography on silica gel using
mixture of CH2Cl2/MeOH = 9/1 or 9/1.2, v/v as an
eluting system.
1,3-Dimethyl-9-(5-(octahydroisoquin-2(1H)-
yl)pentyl)pyrimido[2,1-f]purine-2,4,8(1H,3H,
9H)-trione (8)
Obtained fom I and XV in 50% yield as cream
oil; 1H NMR (300 MHz, CDCl3, δ, ppm): 8.51-8.49
(d, 1H, J = 8.1 Hz), 6.23-6.33 (d, 1H, J = 7.1 Hz),
4.34-4.32 (m, 2H), 3.60 (s, 3H), 3.41 (m, 3H), 2.51-
2.15 (m, 6H), 2.06-1.86 (m, 6H); 1.70-1.38 (m,
18H); 13C NMR (CDCl3, δ, ppm): 162.2, 154.8,
153.2, 151.3, 150.1, 130.8, 127.6, 109.3, 58.6, 57.2,
48.4, 42.2, 39.5, 36.4, 32.1, 30.7, 29.1, 29.0, 28.8,
28.0, 27.1, 26.1, 25.8, 24.5, 24.3; Analysis: calcd.
for C24H34N6O3: C, 63.41; H, 7.54; N, 17.49%;
found: C, 62.77; H, 6.66; N, 17.47%. LC/MS m/z
calcd.: 480.55, found: 481.33.
7-Bromo-1,3-dimethyl-9-(4-(octahydroisoquin-
2(1H)-yl)butyl)pyrimido[2,1-f]purine-2,4,8(1H,
3H,9H)-trione (9)
Obtained from I and XVI in 45% yield as
cream oil; 1H NMR (300 MHz, CDCl3, δ, ppm): 6.23
(s, 1H), 4.34-4.32 (m, 2H), 3.60 (s, 3H), 3.41 (m,
3H), 2.51-2.41 (m, 2H), 2.40-2.15 (m, 4H); 1.70-
1.38 (m, 16H); 13C NMR (CDCl3, δ, ppm): 155.8,
154.0, 151.3, 149.5, 146.2, 133.7, 104.2, 100.4,
57.9, 57.4, 53.5, 44.2, 40.0, 38.1, 31.4, 29.7, 29.4,
27.9, 26.5, 25.6, 24.9, 23.9, 23.1; Analysis: calcd.
for C23H31BrN6O3: C, 53.18; H, 6.02; N, 16.18%;
found: C, 53.27; H, 6.36; N, 16.07%. LC/MS m/z
calcd.: 519.43, found: 521.21.
9-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-
2(1H)-yl)butyl)-1,3-dimethyl-pyrimido[2,1-
f]purine-2,4,8(1H,3H,9H)-trione (10)
Obtained from I and XVII in 46% yield as
cream oil, 1H NMR (300 MHz, CDCl3, δ, ppm):
8.51-8.49 (d, 1H, J = 8.1 Hz), 6.53-6.60 (m, 2H),
6.32-6.31 (d, 1H, J = 7.1 Hz), 4.40 (t, 2H, J = 3.1
Hz), 3.86-3.81 (m, 6H), 3.60 (s, 3H), 3.41 (m, 3H),
2.88-2.83 (m, 4H), 2.79-2.76 (m, 2H), 2.60-2.57 (m,
2H), 2.06-1.86 (m, 4H); 13C NMR (CDCl3, δ, ppm):
162.2, 154.8, 153.2, 151.3, 150.1, 130.8, 127.6,
108.5, 58.6, 56.9, 48.4, 42.1, 39.5, 36.4, 32.1, 30.7,
29.1, 29.0, 28.8, 26.1, 25.8, 25.5, 24.9, 24.5, 24.3;
Analysis: calcd. for C25H30N6O5: C, 60.72; H, 6.11;
N, 16.99%; found: C, 60.77; H, 6.27; N, 17.07.
LC/MS m/z calcd.: 494.54, found: 495.29.
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9-(5-(6,7-Dimethoxy-3,4-dihydroisoquinolin-
2(1H)-yl)pentyl)-1,3-dimethyl-pyrimido[2,1-
f]purine-2,4,8(1H,3H,9H)-trione (11)
Obtained from II and XV in 46% yield as
cream oil, 1H NMR (300 MHz, CDCl3, δ, ppm):
8.51-8.49 (d, 1H, J = 8.1 Hz), 6.53-6.60 (m, 2H),
6.33-6.23 (m, 1H), 4.37-4.20 (m, 2H), 3.86-3.81 (m,
6H), 3.60-3.39 (m, 8H), 2.88-2.76 (m, 2H), 2.79-
2.76 (m, 4H), 2.60-2.57 (m, 2H), 2.06-1.86 (m, 6H);
13C NMR (CDCl3, δ, ppm): 161.8, 153.8, 152.8,
150.3, 150.1, 148.7, 147.8, 145.7, 127.6, 126.5,
109.4, 108.5, 110.3, 60.4, 57.1, 56.9, 56.6, 56.0,
45.1, 30.7, 29.1, 29.0, 28.8, 26.1, 25.8, 24.9.
Analysis: calcd. for C26H32N6O5: C, 61.40; H, 6.34;
N, 16.52%; found: C, 61.17; H, 6.27; N, 16.57%.
LC/MS m/z calcd.: 508.56, found: 509.31.
7-Bromo-9-(4-(6,7-dimethoxy-3,4-dihydroiso-
quinolin-2(1H)-yl)butyl)-1,3-dimethyl-pyrimi-
do[2,1-f]purine-2,4,8(1H,3H,9H)-trione (12)
Obtained from II and XVI in 38% yield as
cream oil; 1H NMR (300 MHz, CDCl3, δ, ppm):
6.53-6.60 (m, 2H), 6.32-6.31 (d, 1H, J = 7.1 Hz),
4.40 (t, 2H, J = 3.1 Hz), 3.86-3.81 (m, 6H), 3.60 (s,
3H), 3.41 (m, 3H), 2.88-2.83 (m, 4H), 2.79-2.76 (m,
2H), 2.60-2.57 (m, 2H), 2.06-1.86 (m, 4H); 13C
NMR (CDCl3, δ, ppm): 162.2, 154.8, 153.2, 151.3,
150.1, 149.1, 146.4, 134.8, 127.6, 126.8, 111.2,
109.5, 59.7, 57.1, 56.8, 56.4, 56.0, 55.4, 40.1, 30.7,
29.1, 29.0, 28.8, 27.1, 25.8, 25.5, Analysis: calcd.
for C25H29BrN6O5: C, 53.36; H, 5.10; N, 14.66%;
found: C, 53.25; H, 5.27; N, 14.77%. LC/MS m/z
calcd.: 573.43, found: 575.26.
In vitro radioligand binding assays
Radioligand binding assays were employed
for determining the affinity and the selectivity pro-
file of the synthesized compounds for cloned 5-
HT1A, 5-HT6, 5-HT7 and dopamine D2 receptors.
This was accomplished by displacement of respec-
tive radioligands from cloned human receptors, all
stably expressed in HEK293 cells: [3H]-8-hydroxy-
2-(di-n-propylamino)tetralin (8-OH-DPAT) for 5-
HT1A, [3H]-LSD for 5-HT6, [3H]-5-carboxami-
dotryptamine (5-CT) for 5-HT7, and [3H]-raclopride
for D2 receptor. All the in vitro radioligand assays
were carried out using methods published by Zajdel
et al. (13). 
Prediction of logP values
The octanol-water partitioning coefficients
(logP) were predicted from structures, using frag-
ment-based algorithm of ACD/Labs ChemSketch
free software. Calculated values were based on an
experimental data set of over 18,000 reliable logP
measurements. 
The phosphodiesterase activity tests
Activity of newly synthesised compounds
towards PDE4A and PDE10A was measured using
the bioluminescent detection system, based on the
activity of PDEs which utilized cAMP as their pref-
Table 1. Binding affinities and calculated log P values of the synthesized tricyclic theophylline derivatives with octahydro- and 6,7-
dimethoxy-3,4-dihydro-isoquinolin-2(1H)-yl)alkyl moieties (1-12).
Ki (nM)Comp. 
5-HT1A 5-HT6 5-HT7 D2
Log PACD
1 9 3338 413 370 4.10
2 90 9532 4642 1701 4.38
3 340 3767 2465 1966 4.56
4 281 4134 2665 1125 4.84
5 22 925 6011 2880 3.03
6 147 1900 4020 865 3.32
7 120 8666 4892 1189 3.49
8 1399 3948 4434 1460 3.77
9 139 5364 3729 1399 3.90
10 115 2788 5040 2815 2.48
11 88 1904 4209 2215 2.71
12 83 2038 4490 1422 2.83
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erential second messenger. Inhibition of PDE4B1
and PDE10A was measured using PDElight HTS
cAMP phosphodiesterase assay kit (PDELightTM,
Lonza) according to manufacturerís recommenda-
tions (14, 15). cAMP measurements were performed
with homogeneous TR-FRET immunoassay using
the LANCE Ultra cAMP kit (PerkinElmer, USA).
Luminescence was measured in a multifunctional
microplate reader (POLARstar Omega, BMG
Labtech, Germany). The percentage of inhibition
was calculated to vehicle control (DMSO). 
RESULTS AND DISCUSSION
The final derivatives of 1,3-dimethyl-(1H)-
imidazo[2,1-f]purine-2,4-(3H,8H)-diones 1ñ7 were
obtained in a reaction of cyclocondensation of 7-
ketonyl derivatives of 8-bromotheophylline
(XIIIñXIV) with appropriate amine (IXñXII)
according to the previously reported method (8).
The target compounds 8ñ12 were synthesized by the
substitution reaction of 1,3-dimethylpyrimido[2,1-
f]purine-2,4,8-(1H,3H,9H)-triones (9) (XVñXVII)
with appropriate amine (I, II) using microwave radi-
ation. The obtained compound structures were con-
firmed with 1H-NMR and 13C-NMR spectra and their
masses were proved with LC/MS analysis.
All the newly synthesized compounds were
tested in competition binding experiments for 5-
HT1A, 5-HT6, 5-HT7, and D2 receptors. The observed
activity of the compounds was variable depending
on the receptor subtype (Table 1). Compounds dis-
played high-to-low affinity for the tested 5-HT1ARs
(Ko from 9 to 1399 nM), lack of activity for 5-HT6Rs
(exception comp. 5 Ko = 925) and for 5-HT7Rs
(exception comp. 1 Ko = 413) and for D2Rs (excep-
tions comp. 1 and 6 with Ko = 370 and 865, respec-
tively).
The activity of newly synthesized compounds
toward PDEB1A and PDE10A was measured using
the bioluminescent detection system, based on the
activity of PDEs which utilized second messenger
cAMP. The AMP produced from the hydrolysis of
cAMP was quantified using the AMP detection
reagent that converts AMP directly to ATP. The bio-
luminescent assay uses luciferase, which catalyzes
the formation of light from the newly formed ATP
and luciferin. The percentage of inhibition was cal-
culated using DMSO as vehicle control. Rolipram,
papaverine, and 3-isobutyl-1-methylxanthine
(IBMX) were used as standards for inhibition poten-
cy for PDE4B1A and PDE10A. Compounds and
standards were tested in screening assays in three
concentrations from 10-4 to 10-5.5 M (Table 2).
Investigated compounds had no inhibitory potencies
for PDE4B1 and PDE10A with two exceptions,
compounds 5 and 11. In concentration of 10-4 M
compound 5 inhibits PDE4B1 in 15% and PDE10A
in 34% whereas compound 11 in 14% and 52%,
respectively. It is noteworthy that compounds 5 and
11 were more potent inhibitors than theophylline,
which was inactive under test condition.
Unfortunately, in lower concentrations their activity
significantly decreased in comparison to standards.
The results obtained for compounds 5 and 11 sug-
gested some impact of introduction of 6,7-dime-
toxy-3,4-dihydro-isoquinolin-2(1H)-yl)alkyl moiety
on inhibitory activity, especially for PDE10A. 
An impact of introduction of octahydroiso-
quin-2(1H)-yl or 6,7-dimetoxy-3,4-dihydro-iso-
quinolin-2(1H)-yl)alkyl (instead of LCAP) moiety
on receptors affinity was evident after analyzing
structure-activity relationships. Such a substitution
causes a significant decrease in receptor activity in
comparison with analogues with LCAP moiety. This
effect is more pronounced for derivatives of 1,3-
Table 2. Inhibition of PDE (%) of tricyclic theophylline derivatives with 6,7-dimethoxy-3,4-dihydro-isoquinolin-2(1H)-yl)alkyl moieties
(comp. 5 and 11).
PDE 4B1a PDE 10Aa
Compound 10-4 10-5 10-5.5 10-4 10-5 10-5.5
5 15 0 - 34 20 -
11 14 7 4 52 21 -
Theophylline - 3 8 - 2 -5
Papaverine 51 13 - 97 78 57
IBMX - 5 - - 98 -
Rolipram 95 84 75 - 3 8
apercentage of inhibition of PDE was calculated in relation to vehicle control (DMSO).
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dimethylpyrimido[2,1-f]purine-2,4,8-(1H,3H,9H)-
trione. The affinity for 5-HT1ARs depended mostly
on the type of the purine core and the length of the
alkylene spacer between purine core and nitrogen
atom of amine. Derivatives of 1,3-dimethyl-(1H)-
imidazo[2,1-f]purine-2,4-(3H,8H)-diones displayed,
in general, higher affinity, especially for 5-HT1A,
than their counterparts, e.g., compounds 2 vs. 8.
Compounds 1 and 5 being the most active ones
belong to the group of 1,3-dimethyl-(1H)-imida-
zo[2,1-f]purine-2,4-(3H,8H)-dione lacking a sub-
stituent at 7-position. Moreover, for derivatives of
1 ,3-d imethylpyr imido[2 ,1- f ]pur ine-2 ,4 ,8-
(1H,3H,9H)-trione, the presence of high lipophilic
bromine substituent at 7 position seems to be more
essential for 5-HT1A activity (8 vs. 9 and 10 vs. 12).
Interestingly, affinity for other receptors (5-HT6, 5-
HT7, and D2) was not significantly influenced by a
type of the xanthine core and the length of alkylene
spacer. 
For further explanation of the structure-activi-
ty relationships and as a continuation of our previ-
ous studies on physicochemical properties of tri-
cyclic theophylline derivatives, logP parameters
were predicted (16). The observed values of logP
were between 2.48 and 4.84 (Table 1). In general,
the highest logP values were observed for octahy-
droisoquin-2(1H)-yl derivatives of imidazo- and
pyrimidino[2,1-f]purines (compounds 1-4 and 8, 9).
Introduction of 6,7-dimetoxy-3,4-dihydro-iso-
quinolin-2(1H)-yl moiety caused a significant
decrease of logP values, especially pronounced for
pyrimidino[2,1-f]purine core (comp. 8 vs. 11).
Analyzing the impact of lipophilicity on receptor
affinity, no relationship between logP values and Ko
was observed. Compounds with the lowest and
highest logP value were inactive in radioligand
receptor binding studies. However, the most potent
compound (1) showed quite high logP value (4.10).
Referring obtained logP values to the rule of five
(17), it seems that all compounds could easily pen-
etrate blood-brain barrier (BBB) and other mem-
brane in the body (logP < 5).
CONCLUSION
In summary, a series of 12 new octahydro- and
6,7-dimetoxy-3,4-dihydro-isoquinolin-2(1H)-yl-
alkyl derivatives of imidazo- and pyrimidino[2,1-
f]purines were synthetized. An introduction of
octahydroisoquin-2(1H)-yl or 6,7-dimetoxy-3,4-
dihydro-isoquinolin-2(1H)-yl)alkyl moiety to the
tricyclic theophylline derivatives was to check the
possibility of obtaining compounds with dual mech-
anism of action: receptor-dependent and receptor-
independent. 
The study allowed the identification of two
potent 5-HT1AR ligands (comp. 1 and 5) and two
weak inhibitors of PDE10A (comp. 5 and 11). This
preliminary study showed that compound 5 (8-(4-
( 6 , 7 - d i m e t h o x y - 3 , 4 - d i h y d r o i s o q u i n o l i n -
2(1H)butyl)1,3-dimethyl-1H-imidazo[2,1-f]purine-
2,4(3H,8H)-dione) could be regarded as promising
structure for further modification and detailed mech-
anistic study for obtaining hybrid ligands. 
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